Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions

References

• UNAIDS fact sheet. http://www.unaids.org/sites/default/files/media_asset/20150901_FactSheet_2015_en.pdf
   Google Scholar
• CDC HIV/AIDS statistics. http://www.cdc.gov/hiv/statistics/overview/ataglance.html
   Google Scholar
• CDC news release. http://www.cdc.gov/nchhstp/newsroom/2016/croi-2016.html
   Google Scholar
• Gray GE, Laher F, Doherty T, Abdool Karim S, Hammer S, Mascola J, Beyrer C, Corey L. Which new health technologies do we need to achieve an end to HIV/AIDS? PLoS Biol 2016; 14:e1002372; PMID:26933962; http://dx.doi.org/10.1371/journal.pbio.1002372
   PubMedGoogle Scholar
• Grant R, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99; PMID:21091279; http://dx.doi.org/10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T, Henderson F, Pathak S, Soud F, Chillag K, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34; PMID:22784038; http://dx.doi.org/10.1056/NEJMoa1110711
   PubMed Web of Science ®Google Scholar
• Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J, Tappero J, Bukusi E, Cohen C, Katabira E, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410; PMID:22784037; http://dx.doi.org/10.1056/NEJMoa1108524
   PubMed Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083-90; PMID:23769234; http://dx.doi.org/10.1016/S0140-6736(13)61127-7
   PubMed Web of Science ®Google Scholar
• McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R, Sullivan A, Clarke A, Reeves I, Schembri G, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2015; 387:53-60; PMID:26364263; http://dx.doi.org/10.1016/S0140-6736(15)00056-2
   PubMed Web of Science ®Google Scholar
• Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A and the ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373:2237-46; PMID:26624850; http://dx.doi.org/10.1056/NEJMoa1506273
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-22; PMID:22784040; http://dx.doi.org/10.1056/NEJMoa1202614
   PubMed Web of Science ®Google Scholar
• Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509-18; PMID:25651245; http://dx.doi.org/10.1056/NEJMoa1402269
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm
   Google Scholar
• CDC PrEP guidelines. http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf
   Google Scholar
• WHO HIV guidelines. http://www.who.int/hiv/pub/guidelines/keypopulations/en/
   Google Scholar
• CDC media release. http://www.cdc.gov/nchhstp/newsroom/2016/croi-2016.html
   Google Scholar
• Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L, Kharsany A, Sibeko S, Mlisana K, Omar Z, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.; http://dx.doi.org/10.1126/science.1193748
   PubMed Web of Science ®Google Scholar
• Rees H, Delany-Moretlwe S, Lombard C, Baron D, Panchia R, Myer L, Schwartz J, Doncel GF, Gray G. FACTS 001 Phase III trial of periocoital tenofovir 1% gel for HIV prevention in women. Conference on Retroviruses and Opportunistic infections 2015, Seattle, WA.
   Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, et al. and MTN-020–ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 2016; [epub ahead of print]; http://dx.doi.org/10.1056/NEJMoa1506110
   PubMed Web of Science ®Google Scholar
• Nel A, Kapiga S, Bekker LG, Devlin B, Borremans M, Rosenberg Z, for the IPM 027/Ring Study Research Center Teams. Safety and efficacy of dapivirine vaginal ring for HIV-1 prevention in African women. Conference on Retroviruses and Opportunistic infections 2016, Boston. LB 110
   Google Scholar
• Harmon T, Fisher K, McGlynn M, Stover J, Warren M, Teng Y, Näveke A. Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV/AIDS response in low- and middle-income countries. PLos One 2016; 11:e0146387; PMID:26731116; http://dx.doi.org/10.1371/journal.pone.0146387
   PubMed Web of Science ®Google Scholar
• Barouch DH, Michael NL. Accelerating HIV-1 vaccine efficacy trials. Cell 2014; 159:969-72; PMID:25416935; http://dx.doi.org/10.1016/j.cell.2014.10.046
   PubMed Web of Science ®Google Scholar
• Excler JL, Robb ML, Kim JH. Prospects for a globally effective HIV-1 vaccine. Am J Prev Med 2015; 49:S307-18; PMID:26590431; http://dx.doi.org/10.1016/j.amepre.2015.09.004
   PubMedGoogle Scholar
• Sheets R, Zhou T, I K. Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned: A review from a regulatory perspective. Biologicals 2015; 44:73-89; PMID:26776940; http://dx.doi.org/10.1016/j.biologicals.2015.10.004
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. Infect Dis 2006; 194:1661-71; http://dx.doi.org/10.1086/508748
   Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65; PMID:15688278; http://dx.doi.org/10.1086/428404
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; PMID:19012954; http://dx.doi.org/10.1016/S0140-6736(08)61591-3
   PubMed Web of Science ®Google Scholar
• Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11:507-15; PMID:21570355; http://dx.doi.org/10.1016/S1473-3099(11)70098-6
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083-92; PMID:24099601; http://dx.doi.org/10.1056/NEJMoa1310566
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Berger JO, Stablein B, Becker S, Essex M, Hammer SM, Kim JM, DeGruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: A case study for statistical issues in efficacy trials. J Infect Dis 2011; 203:969-75; PMID:21402548; http://dx.doi.org/10.1093/infdis/jiq152
   PubMed Web of Science ®Google Scholar
• Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial. Ann Rev Med 2015; 66:1275-1286.
   Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoa1113425
   PubMed Web of Science ®Google Scholar
• Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med 2015; 310rv7:1-10
   Google Scholar
• Sheets R, Zhou T, Knezevic I. Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective. Biologicals 2015; 44:90-110; PMID:26732973; http://dx.doi.org/10.1016/j.biologicals.2015.11.003
   PubMed Web of Science ®Google Scholar
• AIDS Vaccine Advocacy Coalition. http://www.avac.org/trial/hvtn-702
   Google Scholar
• HIV Prevention Trial Network. http://www.hptn.org/research_studies
   Google Scholar
• Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, et al. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol 2016; 17:57-65; PMID:26827165; http://dx.doi.org/10.1016/j.coviro.2016.01.007
   PubMed Web of Science ®Google Scholar
• Excler J, Rida W, Priddy F, Gilmour J, McDermott A, Kamali A, Anzala O, Mutua G, Sanders E, Koff W, et al. AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses 2011; 27:669-80; PMID:21043994; http://dx.doi.org/10.1089/aid.2010.0206
   PubMed Web of Science ®Google Scholar
• Janes H, Gilbert P, Buchbinder S, et al. In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective non vaccine prevention modalities. AIDS Res Hum Retroviruses 2013; 11:1513-23; http://dx.doi.org/10.1089/aid.2012.0385
   Web of Science ®Google Scholar
• Veazey RS. Animal models for microbicide safety and efficacy testing. Curr Opin HIV AIDS 2013; 8:295-303; PMID:23698560
   PubMed Web of Science ®Google Scholar
• Pegu P, Vaccari M, Gordon S, Keele B, Doster M, Guan Y, Ferrari G, Pal R, Ferrari M, Whitney S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87:1708-19; PMID:23175374; http://dx.doi.org/10.1128/JVI.02544-12
   PubMed Web of Science ®Google Scholar
• Cheng-Mayer C, Huang Y, Gettie A, Tsai L, Ren W, Shakirzyanova M, Sina S, Trunova N, Blanchard J, Jenkins L, et al. Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide. AIDS 2011; 25:1833-41; PMID:21750420; http://dx.doi.org/10.1097/QAD.0b013e32834a1d94
   PubMed Web of Science ®Google Scholar
• Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci U S A 2012; 109:8694-8; PMID:22586094; http://dx.doi.org/10.1073/pnas.1203183109
   PubMed Web of Science ®Google Scholar
• LeGrand R, Bosquet N, Dispinseri S, Hopewel N, Gosse L, Desjardins D, Shen X, Tolazzi M, Ochsenbauer C, Saidi H, et al. Microbicide-vaccine combination provides significant protection against vaginal SHIV 162P3 challenge in cynomolgous monkeys. HIV Research for Prevention Conference, Durban, SA, October 2014. Abstract A08.06 LB.
   Google Scholar
• Baggaley R, Dimitrov D, Owen B, Pickles M, Butler A, Masse B, Boily M. Heterosexual anal intercourse: a neglected risk factor for HIV? Am J Reprod Immunol 2013; 69:95-105; PMID:23279040; http://dx.doi.org/10.1111/aji.12064
   PubMed Web of Science ®Google Scholar
• Ross TM, Pereira LE, Luckay A, McNicholl JM, García-Lerma JG, Heneine W, Eugene HS, Pierce-Paul BR, Zhang J, Hendry RM, Smith JM. A polyvalent clade B VLP HIV vaccine combined with partially protective Truvada pre-exposure prophylaxis prevents SHIV infection in macaques and primes for virus-amplified immunity. AIDS Res Hum Retroviruses 2014; 30:1072-81; PMID:24914761; http://dx.doi.org/10.1089/aid.2014.0030
   PubMed Web of Science ®Google Scholar
• McBurney S, Landucci G, Forthal D, Ross T. Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses 2012; 28:1063-72; PMID:22214267
   PubMed Web of Science ®Google Scholar
• García-Lerma J, Cong M, Mitchell J, Youngpairoj A, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2:14ra4
   PubMed Web of Science ®Google Scholar
• HPTN 083 trial. http://www.hptn.org/research_studies/hptn083.asp
   Google Scholar
• García-Lerma J, Aung W, Cong M, Zheng Q, Youngpairoj A, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011; 85:6610-7; http://dx.doi.org/10.1128/JVI.00311-11
   PubMed Web of Science ®Google Scholar
• Melchjorsen J, Risør MW, Søgaard OS, O'Loughlin KL, Chow S, Paludan SR, Ellermann-Eriksen S, Hedley DW, Minderman H, Østergaard L, Tolstrup M. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr 2011; 57:265-75; PMID:21471820; http://dx.doi.org/10.1097/QAI.0b013e3182185276
   PubMed Web of Science ®Google Scholar
• NIH news release. http://www.niaid.nih.gov/news/newsreleases/2016/Pages/HOPE-trial.aspx
   Google Scholar
• Initiative for Multipurpose Prevention Technology. http://mpts101.org
   Google Scholar
• Karim SSA. HIV pre-exposure prophylaxis in injecting drug users. Lancet 2013; 381(9883):2060–2062; http://dx.doi.org/10.1016/S0140-6736(13)61140-X
   Google Scholar